- In October 2024, Arcutis Biotherapeutics received approval from Health Canada for its ZORYVE (roflumilast) foam, a once-daily topical phosphodiesterase-4 (PDE4) inhibitor for seborrheic dermatitis. This follows the FDA approval in December 2023. The company expects to commercially launch ZORYVE in Canada by the end of 2024. With over 168,000 prescriptions already filled in the U.S., the approval marks a significant step in expanding access to effective, steroid-free treatment options for patients suffering from seborrheic dermatitis
- In March 2024, Glenmark Pharmaceuticals launched a new anti-seborrheic shampoo in the Indian market containing selenium sulfide and herbal extracts, aiming to combine clinical efficacy with consumer demand for natural products. The launch is part of the company’s broader strategy to expand its dermatology portfolio in emerging markets with high seborrheic dermatitis burden
- In January 2024, Novartis AG initiated Phase II clinical trials for a topical JAK inhibitor specifically formulated for seborrheic dermatitis. The trial, conducted in collaboration with leading dermatology institutes in the U.S. and Germany, is evaluating the product's safety and efficacy in reducing inflammation and flaking without the side effects associated with corticosteroids. Results are expected by mid-2025 and could potentially position Novartis as a key innovator in the treatment space
